Eric D., MortensonYang-Xin, Fu. (2013) Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. Current Pathobiology Reports 1 , 37-42 /Eric D. Mortenson, Yang-Xin Fu. (2013) Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. Current Pathobiology Reports 1 , 37-42 /...
neu positive breast cancer cell 阳性乳腺癌细胞
HER-2/neu expression in primary and metastatic breast cancer IntroductionTrastuzumab is a highly effective therapy for the treatment of HER-2/neu positive breast cancer. To maximize benefit and minimize unnecessary t... EE Lower,E Glass,R Blau,... - 《Breast Cancer Research & Treatment》 被引...
cancer vaccine design, the role of CD4+ T cells in the memory differentiation of CD8+ T cells and retention of their anti-tumor function have never been tested in breast cancer model. Using the FVB mouse model of neu-positive breast carcinoma we report for the first time that helpless T...
These findings implicate PEA3 in the initiation and progression of HER2/Neu positive breast cancer, and suggest that PEA3 and signaling proteins affecting its regulation are appropriate therapeutic targets. This is a preview of subscription content, log in via an institution to check access. ...
S6. Association between the progesterone receptor and HER-2/neu in oestrogen receptor-positive breast cancerdoi:10.1016/j.ejcsup.2004.08.044elsevierEuropean Journal of Cancer SupplementsHuang HJ, Neven P, Vanspauwen R, et al. Association between the progesterone receptor and HER-2/neu status in ...
–Positive Adjuvant Breast Cancer in the United States Danese MD, Lalla D, Brammer M, et al (Outcomes Insights, Inc, Newbury Park, CA; Genentech, Inc, South San Francisco, CA; et al) Cancer 116:5575-5583, 2010§ K.E. Hoffman x K.E. Hoffman Search for articles by this author, MD...
HER-2/neu status is important information that is needed to guide therapy in patients with HER-2/neu positive breast cancer; therefore, accurate determination of HER-2/neu status by IHC or FISH is essential to providing appropriate treatment. Many studies now demonstrate that the HER-2/neu sta...
negative for Bcl-2 expression (P < 0.001), positive for the epidermal growth factor receptor (P = 0.003), and a high level of p53 (P < 0.001) and Ki-67 expression (P < 0.00). The relapse rates during the follow-up period (median 56.8 months) were 14.7% for TN breast cancer and...
The phase III trial (NCT01479244; Table 2), with nelipepimut-S as a single agent, involved 758 patients with early-stage, node-positive breast cancer with low to intermediate Her-2/neu expression. Patients received nelipepimut-S plus GM-CSF or GM-CSF alone, over the course of six intra...